Main Metabolic Pathways of TAK-802, a Novel Drug Candidate for Voiding Dysfunction, in Humans: The Involvement of Carbonyl Reduction by 11β-hydroxysteroid Dehydrogenase 1

Drug Research

Volumn 64, Issue 9, 2013, Pages 476-484

  Nishihara, M ^a   Takahashi, J ^a   Kondo, T ^a   Mouri, K ^a   Asahi, S ^a  

^a TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

11 hydroxysteroid dehydrogenase (11 HSD); CYP; metabolism; species difference; TAK 802

Indexed keywords

11BETA HYDROXYSTEROID DEHYDROGENASE 1; CHOLINESTERASE INHIBITOR; CYTOCHROME P450 1A2; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; TAK 802; UNCLASSIFIED DRUG; 8-(3-(1-((3-FLUOROPHENYL)METHYL)-4-PIPERIDINYL)-1-OXOPROPYL)-1,2,5,6-TETRAHYDRO-4H-PYRROLO(3,2,1-IJ)QUINOLIN-4-ONE; CYTOCHROME P450 3A; GLYCYRRHETINIC ACID; PYRROLE DERIVATIVE; QUINOLONE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG TRANSFORMATION; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MICTURITION DISORDER; NONHUMAN; NORMAL HUMAN; SPECIES DIFFERENCE; TANDEM MASS SPECTROMETRY; ANIMAL; CLINICAL TRIAL; DOG; DOSE RESPONSE; HAPLORHINI; METABOLISM; PHASE 1 CLINICAL TRIAL; RAT;

11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1; ANIMALS; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCYRRHETINIC ACID; HAPLORHINI; HUMANS; MALE; MICROSOMES, LIVER; PYRROLES; QUINOLONES; RATS; SPECIES SPECIFICITY;

EID: 84929510029     PISSN: 21949379     EISSN: 21949387     Source Type: Journal    
DOI: 10.1055/s-0033-1363221     Document Type: Article

References (20)

1. Ishichi Y., Sasaki M., Setoh M. et al. Novel acetylcholinesterase inhibitor as increasing agent on rhythmic bladder contractions: SAR of 8-{3-[1-(3-fluorobenzyl)piperidin-4-yl]propanoyl}-1,2,5,6-tetrahydro-4 H -pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) and related compounds. Bioorg Med Chem: 2005; 13 1901 1911
2. Nagabukuro H., Okanishi S., Doi T. Effects of TAK-802, a novel acetylcholinesterase inhibitor, and various cholinomimetics on the urodynamic characteristics in anesthetized guinea pigs. Eur J Pharmacol: 2004; 494 225 232
3. Hashimoto T., Nagabukuro H., Doi T. Effects of the selective acetylcholinesterase inhibitor TAK-802 on the voiding behavior and bladder mass increase in rats with partial bladder outlet obstruction. J Urol: 2005; 174 1137 1141
4. Nagabukuro H., Okanishi S., Imai S. et al. Effects of TAK-802, a novel acetylcholinesterase inhibitor, on distension-induced rhythmic bladder contractions in rats and guinea pigs. Eur J Pharmacol: 2004; 485 299 305
5. Kakehi M., Tagawa Y., Kondo T. et al. Disposition of the new potent acetylcholinesterase inhibitor 8-[3-[1-[(3-fluorophenyl)methyl]-4-piperidiny]-1-oxopropyl]-1,2,5,6-tetrahydro-4 H -pyrrolo[3,2,1-ij]quinolin-4-one (TAK-802) in rats, dogs and monkeys. Drug Res: 2013; 63 293 299
6. Rosemond M. J., Walsh J. S. Human carbonyl reduction pathways and a strategy for their study in vitro. Drug Metab Rev: 2004; 36 335 361
7. Skarydová L., Wsól V. Human microsomal carbonyl reducing enzymes in the metabolism of xenobiotics: well-known and promising members of the SDR superfamily. Drug Metab Rev: 2012; 44 173 191
8. Oppermann U. C., Maser E. Molecular and structural aspects of xenobiotic carbonyl metabolizing enzymes. Role of reductases and dehydrogenases in xenobiotic phase I reactions. Toxicology: 2000; 144 71 81
9. Forrest G. L., Gonzalez B. Carbonyl reductase. Chem Biol Interact: 2000; 129 21 40
10. Rosemond M. J. St, John-Williams L., Yamaguchi T. et al. Enzymology of a carbonyl reduction clearance pathway for the HIV integrase inhibitor, S-1360: role of human liver cytosolic aldo-keto reductases. Chem Biol Interact: 2004; 147 129 139
11. Oppermann U. C., Filling C., Jörnvall H. Forms and functions of human SDR enzymes. Chem Biol Interact: 2001; 130-132 699 705
12. Odermatt A., Nashev L. G. The glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 has broad substrate specificity: Physiological and toxicological considerations. J Steroid Biochem Mol Biol: 2010; 119 1 13
13. Maser E. Xenobiotic carbonyl reduction and physiological steroid oxidoreduction. The pluripotency of several hydroxysteroid dehydrogenases. Biochem Pharmacol: 1995; 49 421 440
14. Maser E., Friebertshäuser J., Völker B. Purification, characterization and NNK carbonyl reductase activities of 11β-hydroxysteroid dehydrogenase type 1 from human liver: enzyme cooperativity and significance in the detoxification of a tobacco-derived carcinogen. Chem Biol Interact: 2003; 143-144 435 448
15. Sawada H., Hara A., Nakayama T. et al. Comparative studies on distribution and properties of carbonyl reductase in mammalian tissues. Prog Clin Biol Res: 1982; 114 275 289
16. Matsuura K., Bunai Y., Ohya I. et al. Ultrastructural localization of carbonyl reductase in mouse lung. Histochem J: 1994; 26 311 316
17. Nakanishi M., Deyashiki Y., Ohshima K. et al. Cloning, expression and tissue distribution of mouse tetrameric carbonyl reductase. Identity with an adipocyte 27-kDa protein. Eur J Biochem: 1995; 228 381 387
18. Arampatzis S., Kadereit B., Schuster D. et al. Comparative enzymology of 11β-hydroxysteroid dehydrogenase type 1 from six species. J Mol Endocrinol: 2005; 35 89 101
19. Meyer A., Vuorinen A., Zielinska A. E. et al. Formation of threohydrobupropion from bupropion is dependent on 11β-hydroxysteroid dehydrogenase 1. Drug Metab Dispos: 2013; 41 1671 1678
20. Meyer A., Vuorinen A., Zielinska A. E. et al. Carbonyl reduction of triadimefon by human and rodent 11β-hydroxysteroid dehydrogenase 1. Biochem Pharmacol: 2013; 85 1370 1378